Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001429 · ClinicalTrials.gov registry record · Phase 4
Dexmedetomidine Versus Propofol in Vitreoretinal Surgery
A Phase 4 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT01001429 is a Phase 4 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 78 participants.
The verdict
NCT01001429, a Phase 4 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
The investigators would like to determine if using Dexmedetomidine alone or in a reduced dose can prevent or reduce the incidence of adverse effects, while providing adequate sedation, and respiratory stability as compared to propofol.
Interventions
- DRUG propofol
- DRUG Dexmedetomidine infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001429
The ClinicalTrials.gov registry entry for NCT01001429 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which propofol is the first listed.
NCT01001429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001429 about?
NCT01001429 is a clinical study titled "Dexmedetomidine Versus Propofol in Vitreoretinal Surgery". The investigators would like to determine if using Dexmedetomidine alone or in a reduced dose can prevent or reduce the incidence of adverse effects, while providing adequate sedation, and respiratory stability as compared to propofol.
What is the current status of trial NCT01001429?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2009-10. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01001429?
The interventions under investigation include: propofol (DRUG), Dexmedetomidine infusion (DRUG).
Who is sponsoring clinical trial NCT01001429?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.